October 5: Matt Eckler of Samsara BioCapital joins the board. The NDA for rezatapopt in TP53 Y220C ovarian cancer is still planned for Q1 2027.
PMV Pharmaceuticals (#$PMVP): Can Rezatapopt Build on Ovarian Responses?
www.merlintrader.com/pmv-pharmace...
PMV Pharmaceuticals (#$PMVP): Can Rezatapopt Build on Ovarian Responses?
www.merlintrader.com/pmv-pharmace...
PMV $PMVP: Rezatapopt Data, NDA And Warrant Reset
PMV stock hub: rezatapopt ovarian responses, Q4 2026 data, Q1 2027 NDA plan, cash runway, September financing, warrant reset and dated short interest.
www.merlintrader.com
October 6, 2026 at 9:32 AM
October 5: Matt Eckler of Samsara BioCapital joins the board. The NDA for rezatapopt in TP53 Y220C ovarian cancer is still planned for Q1 2027.
PMV Pharmaceuticals (#$PMVP): Can Rezatapopt Build on Ovarian Responses?
www.merlintrader.com/pmv-pharmace...
PMV Pharmaceuticals (#$PMVP): Can Rezatapopt Build on Ovarian Responses?
www.merlintrader.com/pmv-pharmace...
Obsidian Therapeutics ($OBX): new 6.6% holder
Paradigm Biocapital Advisors: 0 → 6.6%
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 5
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Paradigm Biocapital Advisors: 0 → 6.6%
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 5
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Paradigm Biocapital Advisors LP: 6.6% of Obsidian Therapeutics ($OBX)
Schedule 13G filed Oct 5. Who filed, the stake, and how it changed.
elixstocks.com
October 5, 2026 at 8:02 PM
Obsidian Therapeutics ($OBX): new 6.6% holder
Paradigm Biocapital Advisors: 0 → 6.6%
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 5
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Paradigm Biocapital Advisors: 0 → 6.6%
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 5
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
$PMVP — Officer Change
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors. The company is planning to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian can...
🧵 continued ↓
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors. The company is planning to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian can...
🧵 continued ↓
October 5, 2026 at 3:46 PM
$PMVP — Officer Change
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors. The company is planning to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian can...
🧵 continued ↓
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors. The company is planning to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian can...
🧵 continued ↓
Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases
Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases
Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor..
www.eu-startups.com
October 2, 2026 at 1:10 PM
Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases
Paradigm Biocapital Advisors LP disclosed a 5.1% stake in Spyre Therapeutics ($SYRE), worth about $397M.
A 13G is the passive form: a large holder that is not seeking to influence the company.
#Investing #StockMarket #Stocks
A 13G is the passive form: a large holder that is not seeking to influence the company.
#Investing #StockMarket #Stocks
Paradigm Biocapital Advisors LP: 5.1% of Spyre Therapeutics ($SYRE)
Filed Oct 1. Who filed, the stake, and how it changed.
elixstocks.com
October 1, 2026 at 8:07 PM
Paradigm Biocapital Advisors LP disclosed a 5.1% stake in Spyre Therapeutics ($SYRE), worth about $397M.
A 13G is the passive form: a large holder that is not seeking to influence the company.
#Investing #StockMarket #Stocks
A 13G is the passive form: a large holder that is not seeking to influence the company.
#Investing #StockMarket #Stocks
108 BioCapital Invests $4 Million in SedMed for Expanding Accessibility Solutions#United_States#Danbury#Accessibility_Solutions #108_BioCapital#SedMed_Toilet_Lift
108 BioCapital Invests $4 Million in SedMed for Expanding Accessibility Solutions
108 BioCapital has announced a substantial $4 million investment in SedMed, aimed at enhancing its innovative non-electric toilet lift solutions for individuals with mobility challenges.
third-news.com
October 1, 2026 at 4:09 PM
108 BioCapital Invests $4 Million in SedMed for Expanding Accessibility Solutions#United_States#Danbury#Accessibility_Solutions #108_BioCapital#SedMed_Toilet_Lift
invented symbolic artifact due to artifactual cultural rules that could be entirely changed and contribute basically nothing to biocapital maintenance and replication. and so on.
September 26, 2026 at 5:11 PM
invented symbolic artifact due to artifactual cultural rules that could be entirely changed and contribute basically nothing to biocapital maintenance and replication. and so on.
CellsBin Closes Series A Led by 108 BioCapital: Can Its Rare Cell Intelligence Platform Become Precision Medicine’s New Observational Layer?
US-based CellsBin has raised an undisclosed Series A round led by 108 BioCapital. The company's rare cell intelligence platform aims to add a new…
US-based CellsBin has raised an undisclosed Series A round led by 108 BioCapital. The company's rare cell intelligence platform aims to add a new…
CellsBin Closes Series A Led by 108 BioCapital: Can Its Rare Cell Intelligence Platform Become Precision Medicine’s New Observational Layer?
US-based CellsBin has raised an undisclosed Series A round led by 108 BioCapital. The company's rare cell intelligence platform aims to add a new observational layer to precision medicine.
recodex.pro
September 23, 2026 at 2:32 PM
CellsBin Closes Series A Led by 108 BioCapital: Can Its Rare Cell Intelligence Platform Become Precision Medicine’s New Observational Layer?
US-based CellsBin has raised an undisclosed Series A round led by 108 BioCapital. The company's rare cell intelligence platform aims to add a new…
US-based CellsBin has raised an undisclosed Series A round led by 108 BioCapital. The company's rare cell intelligence platform aims to add a new…
CellsBin Successfully Closes Series A Financing to Enhance Rare-Cell Intelligence Platform#USA#Branford#CellsBin#Rare-Cell_Biology #108_BioCapital
CellsBin Successfully Closes Series A Financing to Enhance Rare-Cell Intelligence Platform
CellsBin has secured Series A financing led by 108 BioCapital to advance its Rare-Cell Intelligence Platform, enhancing precision medicine.
third-news.com
September 22, 2026 at 2:47 PM
CellsBin Successfully Closes Series A Financing to Enhance Rare-Cell Intelligence Platform#USA#Branford#CellsBin#Rare-Cell_Biology #108_BioCapital
Srini Akkaraju turned Stanford immunology into a biotech empire - 93 portfolio companies, 32 IPOs, and he's just getting started
https://yespress.io/srini-akkaraju?utm_source=bluesky&utm_medium=social via Yespress
https://yespress.io/srini-akkaraju?utm_source=bluesky&utm_medium=social via Yespress
Srini Akkaraju
Founder & Managing General Partner of Samsara BioCapital. Stanford immunologist. 93+ portfolio companies. 32 IPO exits.
yespress.io
May 26, 2026 at 6:05 AM
Srini Akkaraju turned Stanford immunology into a biotech empire - 93 portfolio companies, 32 IPOs, and he's just getting started
https://yespress.io/srini-akkaraju?utm_source=bluesky&utm_medium=social via Yespress
https://yespress.io/srini-akkaraju?utm_source=bluesky&utm_medium=social via Yespress
#ACHV Achieve Life Sciences Announces Up to $354 Million Private Placement
https://www.stocktitan.net/news/ACHV/achieve-life-sciences-announces-up-to-354-million-private-2z3qh667jrw3.html
https://www.stocktitan.net/news/ACHV/achieve-life-sciences-announces-up-to-354-million-private-2z3qh667jrw3.html
Achieve Life Sciences Announces Up to $354 Million Private Placement
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace SEATTLE, Wash. and VANCOUVER,
www.stocktitan.net
April 16, 2026 at 12:54 PM
#ACHV Achieve Life Sciences Announces Up to $354 Million Private Placement
https://www.stocktitan.net/news/ACHV/achieve-life-sciences-announces-up-to-354-million-private-2z3qh667jrw3.html
https://www.stocktitan.net/news/ACHV/achieve-life-sciences-announces-up-to-354-million-private-2z3qh667jrw3.html
Connecticut Innovations and Mission BioCapital Join Forces to Propel Biotech Startups in the 2026 Platinum Program#United_States#New_Haven#Mission_BioCapital#Platinum_Program#Connecticut_Innovations
Connecticut Innovations and Mission BioCapital Join Forces to Propel Biotech Startups in the 2026 Platinum Program
Connecticut Innovations partners with Mission BioCapital for the 2026 Platinum Program, aiming to accelerate biotech startups by providing essential resources and funding.
third-news.com
April 6, 2026 at 1:14 PM
Connecticut Innovations and Mission BioCapital Join Forces to Propel Biotech Startups in the 2026 Platinum Program#United_States#New_Haven#Mission_BioCapital#Platinum_Program#Connecticut_Innovations
Mission BioCapital Opens $4 Million competition for Biotech Innovators and 2025 Investments Announced#United_States#Cambridge#Biotech_Innovation#Mission_BioCapital#Platinum_Program
Mission BioCapital Opens $4 Million competition for Biotech Innovators and 2025 Investments Announced
Mission BioCapital unveils the $4 million Platinum Program for biotech start-ups, providing funding and mentorship while seeking innovative applications until May 15, 2026.
third-news.com
April 2, 2026 at 12:29 PM
Mission BioCapital Opens $4 Million competition for Biotech Innovators and 2025 Investments Announced#United_States#Cambridge#Biotech_Innovation#Mission_BioCapital#Platinum_Program
A bleak future for ethics.
Paleogenomics and the fate of human remains in the age of biocapital 🏺🧪
www.tandfonline.com/doi/full/10....
Genomic info detached from notions such as accountability or agency, indirectly placing biologic samples outside of the classic parameters of ethical discussions.
Paleogenomics and the fate of human remains in the age of biocapital 🏺🧪
www.tandfonline.com/doi/full/10....
Genomic info detached from notions such as accountability or agency, indirectly placing biologic samples outside of the classic parameters of ethical discussions.
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
DNA samples taken from prehistoric bones from Europe are now used to explain some of the complex social and cultural processes of the past. But data intensive research is changing how archaeologist...
www.tandfonline.com
March 24, 2026 at 2:02 PM
A bleak future for ethics.
Paleogenomics and the fate of human remains in the age of biocapital 🏺🧪
www.tandfonline.com/doi/full/10....
Genomic info detached from notions such as accountability or agency, indirectly placing biologic samples outside of the classic parameters of ethical discussions.
Paleogenomics and the fate of human remains in the age of biocapital 🏺🧪
www.tandfonline.com/doi/full/10....
Genomic info detached from notions such as accountability or agency, indirectly placing biologic samples outside of the classic parameters of ethical discussions.
This looks relevant to faunal aDNA as well (e.g. use in opaque commercial enterprises that intersect with palaeogenomic research)
👇
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
www.tandfonline.com/doi/full/10....
👇
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
www.tandfonline.com/doi/full/10....
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
DNA samples taken from prehistoric bones from Europe are now used to explain some of the complex social and cultural processes of the past. But data intensive research is changing how archaeologist...
www.tandfonline.com
March 18, 2026 at 9:07 AM
This looks relevant to faunal aDNA as well (e.g. use in opaque commercial enterprises that intersect with palaeogenomic research)
👇
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
www.tandfonline.com/doi/full/10....
👇
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
www.tandfonline.com/doi/full/10....
Arizona and out-of-state investors. Health care leaders. Breakout ask-the-expert sessions, new connections, and insights from J.P. Morgan. We’re only halfway done!
Happening now at the sold-out Flinn Foundation Bio Capital Conference.
#BioCapital #AZBioscience #Healthcare #Networking #AZBioRoadmap
Happening now at the sold-out Flinn Foundation Bio Capital Conference.
#BioCapital #AZBioscience #Healthcare #Networking #AZBioRoadmap
March 5, 2026 at 9:01 PM
Arizona and out-of-state investors. Health care leaders. Breakout ask-the-expert sessions, new connections, and insights from J.P. Morgan. We’re only halfway done!
Happening now at the sold-out Flinn Foundation Bio Capital Conference.
#BioCapital #AZBioscience #Healthcare #Networking #AZBioRoadmap
Happening now at the sold-out Flinn Foundation Bio Capital Conference.
#BioCapital #AZBioscience #Healthcare #Networking #AZBioRoadmap
Vico CEO Micah Mackison is presenting at BioCapital Europe 2026, sharing updates on VO659 and our global strategy for allele-preferential RNA therapies in polyglutamine diseases. Let’s connect!
#BioCapitalEurope #VO659
#BioCapitalEurope #VO659
March 4, 2026 at 9:25 AM
Vico CEO Micah Mackison is presenting at BioCapital Europe 2026, sharing updates on VO659 and our global strategy for allele-preferential RNA therapies in polyglutamine diseases. Let’s connect!
#BioCapitalEurope #VO659
#BioCapitalEurope #VO659
All set for an exciting day at Biocapital Europe in Amsterdam #Inverna #BioCapital2026 #Biotech #RNA #SpliceModulation #Neurodegeneration #ParkinsonsDisease #HuntingtonsDisease #PrecisionMedicine #BiotechInvesting #Partnering
March 4, 2026 at 7:15 AM
All set for an exciting day at Biocapital Europe in Amsterdam #Inverna #BioCapital2026 #Biotech #RNA #SpliceModulation #Neurodegeneration #ParkinsonsDisease #HuntingtonsDisease #PrecisionMedicine #BiotechInvesting #Partnering
Pinwheel Therapeutics raises $20 million from 108 Bio Capital
Pinwheel Therapeutics raises $20 million from 108 Bio Capital
Pinwheel Therapeutics, a clinical stage biopharmaceutical company advancing differentiated therapeutic assets said it has raised $20 million from US-based growth equity fund, 108 BioCapital. Having re...
beyondlink.live
February 7, 2026 at 2:17 PM
Pinwheel Therapeutics raises $20 million from 108 Bio Capital
From Biotech Bay & Biotech Beach in CA. to expanding hubs like Genetown, Pharm Country, BioMidwest, Bio NC, & BioCapital, the life sciences landscape continues to thrive. We are proud to support the organizations driving these ecosystems forward! tinyurl.com/ydpss9av
BioSpace Reveals Fresh Design With 2026 Hotbed Maps, Highlighting Life Sciences Hubs
BioSpace has revealed its new 2026 Hotbed Maps, showcasing seven regional life sciences hot spots.
tinyurl.com
January 22, 2026 at 2:45 PM
From Biotech Bay & Biotech Beach in CA. to expanding hubs like Genetown, Pharm Country, BioMidwest, Bio NC, & BioCapital, the life sciences landscape continues to thrive. We are proud to support the organizations driving these ecosystems forward! tinyurl.com/ydpss9av
AI Proteins has closed a $41.5 million Series A financing to accelerate the development of de novo #miniproteins! The round was led by Mission BioCapital and SANTÉ, with robust participation from existing investors.
See the official press release for details:
www.businesswire.com/news/home/20...
See the official press release for details:
www.businesswire.com/news/home/20...
November 20, 2025 at 8:02 PM
AI Proteins has closed a $41.5 million Series A financing to accelerate the development of de novo #miniproteins! The round was led by Mission BioCapital and SANTÉ, with robust participation from existing investors.
See the official press release for details:
www.businesswire.com/news/home/20...
See the official press release for details:
www.businesswire.com/news/home/20...